Bionano Genomics (BNGO) Cash from Operations (2017 - 2026)

Bionano Genomics has disclosed Cash from Operations across 10 years of filings, most recently posting 5716000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 5716000.0, down 106.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 19297000.0 (up 55.7% YoY), and the FY2025 annual result was 16345000.0, up 76.28% from the prior year.
• Cash from Operations came in at 5716000.0 for Q1 2026 at Bionano Genomics, down from 4145000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 2764000.0 in Q1 2025 to a low of 36696000.0 in Q2 2023.
• The 5-year median for Cash from Operations is 26293000.0 (2023), against an average of 20057647.06.
• Across the five-year window, Cash from Operations plunged 133.7% in 2022 and jumped 90.17% in 2025, its largest moves.
• Bionano Genomics' Cash from Operations stood at 34517000.0 in 2022, then gained by 13.73% to 29779000.0 in 2023, then soared by 78.16% to 6504000.0 in 2024, then surged by 36.27% to 4145000.0 in 2025, then tumbled by 37.9% to 5716000.0 in 2026.
• The last three Cash from Operations figures came in at 5716000.0 (Q1 2026), 4145000.0 (Q4 2025), and 5900000.0 (Q3 2025), per Business Quant data.